Literature DB >> 18591930

Treatment options for benign prostatic hyperplasia in older men.

Roberto Miano1, Cosimo De Nunzio, Anastasios D Asimakopoulos, Stefano Germani, Andrea Tubaro.   

Abstract

BACKGROUND: Benign prostatic enlargement (BPE) is one of the most common diseases in ageing men; it is associated with bothersome lower urinary tract symptoms that affect the individual's quality of life. This review focuses on the different available options for treating benign prostatic hyperplasia (BPH) in older men and on how to choose the right treatment. MATERIAL/
METHODS: A literature search was done to review relevant papers. Relatively recent papers, as well as those in a series or papers from expert centers, are included in the reference list.
RESULTS: Treatment options for BPE in older men include medical therapy, transurethral resection of the prostate (TURP), minimally invasive treatments (ie, transurethral microwave thermotherapy, transurethral needle ablation, and laser surgery) and prostatic stenting. Age, individual anesthesiologic risk, grade of obstruction, prostate volume, serum prostate specific antigen (PSA) value, treatment-related complication rate, presence of an indwelling catheter, and neurologic disorders are factors that should be taken into consideration in choosing an appropriate treatment.
CONCLUSIONS: Given the wealth of treatment options available, physicians must take care to choose the right treatment for each patient, depending on the patient's needs and medical history.

Entities:  

Mesh:

Year:  2008        PMID: 18591930

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  21 in total

1.  The residual nonadrenergic contractile response to nerve stimulation of the mouse prostate is mediated by acetylcholine but not ATP in a comparison with the mouse vas deferens.

Authors:  Carl W White; Jennifer L Short; John M Haynes; Richard J Evans; Sabatino Ventura
Journal:  J Pharmacol Exp Ther       Date:  2010-08-19       Impact factor: 4.030

2.  Ahead of the curve.

Authors:  David B Nash
Journal:  Popul Health Manag       Date:  2013       Impact factor: 2.459

3.  What makes the α(1A)-adrenoceptor gene express the α(1L)-adrenoceptor functional phenotype?

Authors:  Sabatino Ventura
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Safety, efficacy and outcomes of the new GreenLight XPS 180W laser system compared to the GreenLight HPS 120W system for the treatment of benign prostatic hyperplasia in a prospective nonrandomized single-centre study.

Authors:  Alper Eken; Bulent Soyupak; Meltem Acil; Taner Arpaci; Tugana Akbas
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

5.  Effect of an employer-sponsored health and wellness program on medical cost and utilization.

Authors:  Hangsheng Liu; Katherine M Harris; Sarah Weinberger; Seth Serxner; Soeren Mattke; Ellen Exum
Journal:  Popul Health Manag       Date:  2012-07-23       Impact factor: 2.459

Review 6.  What makes the α1A -adrenoceptor gene product assume an α1L -adrenoceptor phenotype?

Authors:  Carl W White; Edilson Dantas da Silva Junior; Linzi Lim; Sabatino Ventura
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

Review 7.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

8.  Inhibitory action of Epilobium hirsutum extract and its constituent ellagic acid on drug-metabolizing enzymes.

Authors:  Gurbet Celik; Aslı Semiz; Serdar Karakurt; Ayse Mine Gencler-Ozkan; Sevki Arslan; Orhan Adali; Alaattin Sen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-11-26       Impact factor: 2.441

9.  Prostatic artery embolization in benign prostatic hyperplasia: preliminary results in 13 patients.

Authors:  Maurizio Grosso; Alberto Balderi; Matteo Arnò; Davide Sortino; Alberto Antonietti; Fulvio Pedrazzini; Grazia Giovinazzo; Claudia Vinay; Orazio Maugeri; Carlo Ambruosi; Giuseppe Arena
Journal:  Radiol Med       Date:  2014-09-23       Impact factor: 3.469

10.  Assessing the Safety and Efficacy of the ClearRing™ Implant for the Treatment of Benign Prostatic Hyperplasia in a Canine Model.

Authors:  Yair Feld; Shai Golan; Ilan Leibovitch
Journal:  Curr Urol       Date:  2018-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.